# Phase 1 Study of Oral TP-1454

> **NCT04328740** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Advanced Solid Tumor
- Anal Cancer

## Interventions

- **DRUG:** TP-1454 monotherapy

## Key facts

- **NCT ID:** NCT04328740
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-08
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328740, "Phase 1 Study of Oral TP-1454". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04328740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*